Regarding metabolic effects due to PPAR-γ activation, although some studies demonstrate an association between its increased expression and the development of fatty liver dystrophy [52], there are also examples of studies where PPAR-γ activation led to reduced inflammation in MASLD [53,54]. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.